{"id":"W3124162597","doi":"10.1002/cncr.33378","title":"Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial","year":2021,"lang":"en","type":"article","venue":"Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Merck","keywords":"Pembrolizumab; Medicine; Glioblastoma; Oncology; Programmed cell death 1; Internal medicine; Cancer research; Cancer; Immunotherapy; PD-L1","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006210327,0.0002839729,0.0004739203,0.00004893715,0.00008806393,0.00005088551,0.00006036589,0.00008300009,0.0000518877],"category_scores_gemma":[0.00007562681,0.0001406588,0.0001362812,0.0002922447,0.00006330606,0.00004541351,0.00002683908,0.0001470292,0.00001295161],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007529766,"about_ca_system_score_gemma":0.0005235117,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001933221,"about_ca_topic_score_gemma":0.005094016,"domain_scores_codex":[0.9983352,0.00008562844,0.00034547,0.0005738965,0.0003033695,0.0003564175],"domain_scores_gemma":[0.9988502,0.0002621911,0.0001141656,0.0004499475,0.0001471162,0.0001763246],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5248246,0.01722769,0.03300622,0.00002218564,0.001841335,0.00732658,0.005522029,0.00002630642,0.001341948,0.00003776249,0.0009123572,0.407911],"study_design_scores_gemma":[0.7763476,0.01859329,0.05502476,0.001000279,0.001688464,0.0001103036,0.0005787959,0.0004054598,0.1268688,0.00002269331,0.01895752,0.0004019523],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888042,0.003872391,0.000004529494,0.004141026,0.0002954187,0.002110422,0.0004603567,0.00003641636,0.0002752172],"genre_scores_gemma":[0.9961808,0.000844543,0.0001837887,0.000168529,0.0004417172,0.001665333,0.0003133282,0.00002998485,0.0001719831],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4075091,"threshold_uncertainty_score":0.5735897,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03357872649936543,"score_gpt":0.3363036082193984,"score_spread":0.302724881720033,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}